Description
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC 50 of 2.3 nM in vivoIn VivoPFE-360 (4 mg/kg and 7.5 mg/kg, orally, BID, 10-12 weeks) treatment potently decreases the LRRK2-pSer935/total LRRK2 ratio, with no significant adverse effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Sprague Dawley rats (NTac:SD) weighed 225-250 g. Dosage: 4 mg/kg and 7.5 mg/kg ( pharmacokinetics and pharmacodynamics ). Administration: Orally BID for 10-12 weeks. Result: The LRRK2-pSer935/total LRRK2 ratio was significantly decreased at both 1 h and 12 h after dosing. The terminal bodyweights exhibited no significant changes.Form:SolidIC50& Target:IC50: 2.3 nM (LRRK2 in vivo)